Lexitas Pharma Services

What Lexitas Pharma Services does

Lexitas Pharma Services is a specialty contract research organization (CRO) focused exclusively on ophthalmology drug and device development. Founded in 2010/2011 (sources differ) and headquartered in Durham, North Carolina, the company operates as a portfolio company of QHP Capital, a healthcare-focused private equity sponsor pursuing a buy-and-build strategy in the ophthalmology CRO space. It serves biopharmaceutical and medical-device sponsors running ophthalmology clinical trials, with a global operational footprint spanning 700+ investigator sites across 70+ countries and access to 3,700+ subject matter experts. The company is led by CEO Jeanne Hecht and reports a workforce of 101-250 employees, with cumulative staff experience of 475+ years and an average tenure of 15+ years in ophthalmology.

The company's core offering is end-to-end clinical research services for ophthalmology sponsors, including protocol design, site identification and management, regulatory support, clinical monitoring, biostatistics, and an integrated Reading Center for ophthalmic imaging analysis. Its proprietary technology platform, iNebula, provides sponsors with real-time visibility into trial status and operational metrics. Recent strategic moves include the May 2026 acquisition of Erie Retina Research, CASExERIE LLC, and Element Erie (Imaging & Reading Center PLLC) to build dedicated retina capabilities, an April 2026 strategic partnership with NAMSA for ophthalmic medical device development, the hire of Dr. David Almeida as Chief Retina Strategy Officer, and entry into cell and gene therapy ophthalmology work. Publicly disclosed customers are predominantly early-stage biotech sponsors: Novus Vision, Ocugenix, Novaliq, ONL Therapeutics, Opus Genetics, jCyte, Levation Pharma, PYC Therapeutics, and Allgenesis.

Lexitas operates on a project-based CRO services model, charging sponsors for full-service clinical trial execution (or functional service provisions) tied to study size, duration, complexity, and geographic footprint. Revenue mechanics are typical of mid-sized specialty CROs: a mix of FTE-based pass-through costs, milestone payments, per-study fees, and managed-pass-through investigator grants. The company is currently expanding both vertically (cell and gene therapy) and geographically (Asia-Pacific) and has begun productizing adjacent device CRO services through the NAMSA partnership.

Name

Lexitas Pharma Services

Legal name

Lexitas Pharma Services Inc.

Website

https://lexitas.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Lexitas Pharma Services is a Durham, NC-based specialty CRO focused exclusively on ophthalmology clinical trials, serving biotech and medical-device sponsors across 700+ investigator sites in 70+ countries, with a proprietary iNebula platform and an integrated Reading Center.

Ownership category

akta.pro rank

Product category

Ophthalmology Clinical Research Services

NAICS

Other Management Consulting Services (541618)

SIC

Services-Health Services (8000)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Ophthalmology CRO services
• Clinical research organization
• Reading center imaging
• Biometrics data management
• Medical regulatory writing

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Operations Services: Full-service clinical research organization providing clinical operations support from study design through close-out, including project management, site relationships, and regulatory coordination for ophthalmic clinical trials.
2. Reading Center Services: In-house image reading and analysis services for clinical trial endpoints, providing biomarker identification, quality assurance, and post-hoc analysis capabilities with real-time trial status updates.
3. Biometrics and Data Management: Data management, biostatistics, and statistical programming services providing tailored guidance throughout the development journey from study design to regulatory submission.
4. Medical and Regulatory Writing: Scientific document production by subject matter experts ensuring regulatory compliance and scientific rigor for clinical trial documentation.
5. Medical Monitoring: Proactive medical and scientific oversight of clinical trial activity by ophthalmology experts to ensure subject safety and trial integrity.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

Lexitas Pharma Services is a full-service ophthalmology Contract Research Organization (CRO) that delivers end-to-end clinical trial services for pharmaceutical, biotechnology, and medical device sponsors. Offerings include clinical operations, an in-house integrated Reading Center for image-based endpoints, biometrics and data management, medical and regulatory writing, medical monitoring, and global regulatory strategy through its Lexitas Global network spanning 70+ countries.

Product overview

Lexitas Pharma Services is a specialized ophthalmology Contract Research Organization (CRO) offering a platform-plus-modules architecture for clinical research services. The core platform provides comprehensive clinical development support, while the modular service offerings include Clinical Operations, Lexitas Global (Regulatory Strategy), Medical & Regulatory Writing, Medical Monitoring, Reading Center Services, and Biometrics. These modules work together as an integrated offering, with Reading Center services being fully integrated with other CRO services to centralize trial processes. The recent acquisitions of Erie Retina Research, CASExERIE, and Element Erie (Imaging & Reading Center) expanded the portfolio to include a fully integrated retina research platform combining clinical trial operations with surgical innovation, training capabilities, device development, and specialized ophthalmic imaging.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Operations Full range of clinical operations services from study design through close-out, leveraging strong ophthalmology site relationships to support planning, implementation, management, and execution of ophthalmic clinical trials for pharmaceutical, biotech, and medical device sponsors.
• Reading Center Services In-house Reading Center delivering customized, cutting-edge image reading and analysis for clinical trial endpoints, fully integrated with other offerings to centralize trial processes, reduce overhead, and avoid delays. Capabilities include SD-OCT, SD-OCTA, fundus photographs, FAF, microperimetry, specular microscopy, AS-OCT, and slit lamp images.
• Biometrics Data Management, Biostatistics, and Statistical Programming services that transform clinical trial data into actionable insights, with tailored guidance supporting every stage of the development journey from study design to regulatory submission.
• Medical and Regulatory Writing Medical writing services where subject matter experts leverage extensive ophthalmology experience to produce scientifically sound documents meeting regulatory requirements, working collaboratively across teams.
• Medical Monitoring Medical and scientific oversight of all clinical trial activity provided by ophthalmology experts to ensure subject safety and trial integrity throughout the study.
• Lexitas Global (Regulatory Strategy) Global regulatory strategy services with a network spanning over 70 countries and connections to over 3,700 local therapeutic experts, addressing operational, regulatory, and market access nuances across regions for ophthalmic sponsors.

Quantifiable outcome

• Delivered last patient-in ahead of schedule for Novaliq
• +2 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• NAMSAcoreStrategic or Co-development Partner · 30 April 2026NAMSA, a global MedTech contract research organization, announced a strategic partnership with Lexitas Pharma Services to provide comprehensive end-to-end product development support for ophthalmic medical device sponsors. The partnership integrates Lexitas's specialized ophthalmic expertise—including over 700 investigator sites and 15 years of dedicated experience—with NAMSA's broader medical device development platform and global reach across the U.S., Europe, and Asia-Pacific. The companies will showcase the partnership at the ARVO Annual Meeting in Denver, Colorado in May 2026.
• Erie Retina ResearchcoreStrategic or Co-development PartnerLexitas acquired Erie Retina Research as part of a strategic expansion of its retina-focused clinical research capabilities. Erie Retina Research becomes a wholly owned subsidiary of Lexitas, enhancing the company's ability to improve efficiency, scientific depth, and operational rigor of retinal clinical trials.
• CASExERIE, LLCcoreStrategic or Co-development PartnerLexitas acquired CASExERIE, LLC as part of the May 2026 acquisition of three entities to enhance its retina-focused clinical research capabilities. CASExERIE becomes part of Lexitas as a wholly owned subsidiary.
• Element Erie: Imaging & Reading Center PLLCcoreStrategic or Co-development PartnerLexitas acquired Element Erie: Imaging & Reading Center PLLC to expand its ophthalmic imaging and research ecosystem. The acquisition integrates specialized ophthalmic imaging reading services into Lexitas's portfolio, establishing a fully integrated retina research platform combining clinical trial operations with surgical innovation, training capabilities, device development, and specialized ophthalmic imaging reading services.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medpace: Medpace is a mid-to-large CRO known for a selective, therapeutically focused operating model and strong scientific leadership. Its specialty-style positioning and full-service clinical operations overlap meaningfully with Lexitas's go-to-market, though Medpace operates across many therapeutic areas.
• Parexel: Parexel is a major global CRO with extensive clinical operations, biometrics, and regulatory services across therapeutic areas including ophthalmology. It serves as another broad incumbent competing for larger ophthalmic engagements.
• Thermo Fisher Scientific (PPD): PPD, now part of Thermo Fisher Scientific, is one of the world's largest CROs with end-to-end clinical development services. It is a relevant broad incumbent competing against specialty CROs for ophthalmic sponsor mandates.
• IQVIA: IQVIA is the world's largest CRO with a broad therapeutic portfolio that includes ophthalmology, large-scale site networks, and proprietary technology platforms. It serves as the dominant incumbent against which specialty CROs like Lexitas differentiate.
• Syneos Health: Syneos Health is a large full-service CRO with clinical and commercial capabilities across multiple therapeutic areas. It competes with Lexitas for ophthalmic sponsors seeking a broad-service partner rather than a pure-play specialist.
• ICON plc: ICON is one of the largest global CROs and operates dedicated ophthalmology and medical device practices with full-service clinical operations, biometrics, and regulatory capabilities. It competes for larger ophthalmic RFPs that Lexitas also targets.

Emerging players

• Rho: Rho is a privately held, therapeutically focused CRO with strong scientific and regulatory expertise across multiple indications. As a smaller specialty CRO, it competes with Lexitas for biotech sponsors seeking scientifically led, mid-sized CRO partners.

Direct peers

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized specialty CRO with deep expertise in neuroscience, ophthalmology, and other complex therapeutic areas. Its specialty-focused model and therapeutic depth make it a closely comparable peer to Lexitas.
• Ora, Inc. Ora is the leading dedicated ophthalmology CRO offering clinical operations, regulatory, and imaging services to pharma and device sponsors. It is the most direct competitor to Lexitas, matching its pure-play ophthalmology focus and integrated Reading Center capabilities.

Regional players

• Novotech: Novotech is an Asia-Pacific focused CRO with growing global reach and increasing activity in ophthalmology and cell/gene therapy trials. It is a relevant peer for cross-region trial execution where Lexitas competes for global sponsor work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lexitas-pharma-services

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lexitas Pharma Services